This resource summarizes guidelines for screening, assessing, and providing comprehensive treatment for issues related to child abuse and neglect among people in substance use disorder treatment. It provides strategies for breaking the intergenerational cycle and discusses therapeutic issues for counselors.

This guide provides strategies for clinicians who provide substance use disorder treatment to people who have experienced child abuse and child neglect. It lists symptoms of child abuse and neglect and presents screening questions, behavioral clues, and the role of child protective services.

This guide educates substance use counselors and clinicians about detoxification and withdrawal. It addresses patient placement, detox services for specific substances, co-occurring disorders, financing issues, and screening and assessment tools.

This brochure informs patients about buprenorphine and medication-assisted treatment for opioid use disorder. It describes addiction and withdrawal, how buprenorphine works, its proper use, its side effects, and how it fits with counseling in the recovery process.

This manual provides guidelines for the operation of opioid treatment programs. It covers patient assessment, treatment planning, and recovery care. The manual also offers guidance for medication-assisted treatment for methadone and buprenorphine, and overdose and relapse prevention.

This brochure is designed to help men deal with child abuse issues that might arise during treatment for substance use disorders. It defines child abuse, lists symptoms of abuse, and describes how counselors can help with coping and healing.

This brochure is designed to help women deal with child abuse issues that might arise during treatment for substance use disorders. It defines child abuse, lists symptoms of abuse, and describes how counselors can help with coping and healing.

This guide reviews child welfare, substance use disorder services, and courts to support cross-system coordination within state, county, and tribal jurisdictions. It considers the framework, population, legislation, funding sources, and services for each system.

This advisory gives an overview of extended-release injectable naltrexone for people with opioid dependence. It discusses how it differs from other medication-assisted treatments, safety concerns, and patients most likely to benefit.

This advisory defines protracted withdrawal and identifies specific withdrawal symptoms associated with alcohol, opioids, methamphetamine, cocaine, marijuana, and benzodiazepines. The advisory also explains how protracted withdrawal differs from acute withdrawal, and gives tips to help clients manage it in recovery.